for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Aduro Biotech Announces Milestone Achieved Under Merck Collaboration For Initiation Of Phase 2 Trial Of Anti-Cd27 Agonist Mk-5890 In Non-Small Cell Lung Cancer

Feb 6 (Reuters) - Aduro Biotech Inc:

* ADURO BIOTECH ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF PHASE 2 TRIAL OF ANTI-CD27 AGONIST MK-5890 IN NON-SMALL CELL LUNG CANCER

* ADURO BIOTECH- EARNED $10 MILLION DEVELOPMENT MILESTONE PAYMENT UNDER WORLDWIDE LICENSING DEAL WITH MERCK FOR PHASE 2 CLINICAL TRIAL OF MK-5890 INITIATION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up